FDA OKs trial of Terumo protocol for polymorphonuclear cells

01/8/2013 | InnovatioNews

The FDA has approved a trial to assess a collection protocol for polymorphonuclear cells using the Spectra Optia platform, according to Terumo BCT. Polymorphonuclear cells from donors could help patients whose immune systems are compromised due to illness or chemotherapy.

View Full Article in:

InnovatioNews

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA